Compare INAB & SINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INAB | SINT |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 11.1M |
| IPO Year | 2020 | 2007 |
| Metric | INAB | SINT |
|---|---|---|
| Price | $1.48 | $1.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 50.0K | 45.2K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,018,000.00 |
| Revenue This Year | N/A | $30.26 |
| Revenue Next Year | N/A | $413.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $1.86 |
| 52 Week High | $2.73 | $6.78 |
| Indicator | INAB | SINT |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 38.89 |
| Support Level | $1.34 | $1.93 |
| Resistance Level | $1.85 | $2.98 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 60.91 | 11.11 |
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.